Join to View Full Profile
20 York StNew Haven, CT 06510
Phone+1 203-688-4242
Fax+1 203-688-5013
Dr. Zeidan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Jordan Faculty of MedicineClass of 2001
Rochester General HospitalResidency, Internal Medicine
Certifications & Licensure
CT State Medical License 2014 - 2026
MD State Medical License 2010 - 2015
NY State Medical License 2007 - 2014
American Board of Internal Medicine Hematology
Clinical Trials
- Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents Start of enrollment: 2017 Jun 23
- Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease Start of enrollment: 2019 Jun 26
- GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
- Join now to see all
Publications & Presentations
PubMed
- Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants.Jinsuke Nishino, Wenhuo Hu, Ashwin Kishtagari, Bo Shen, Xiang Gao
Cancer Discovery. 2025-04-02 - A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan
Future Oncology. 2025-04-01 - A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome.Guillermo Garcia-Manero, Manila Gaddh, Uwe Platzbecker, R Coleman Lindsley, Sarah M Larson
Annals of Hematology. 2025-03-28
Lectures
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice60th American Society of Hematology Annual Meeting - 11/30/2018
Press Mentions
Is AML Harder to Treat After Relapse?March 6th, 2020
Trovagene (TROV) Stock: Providing New Cancer Treatment Options with OnvansertibDecember 11th, 2018
Breaking News: Trovagene Reports New Data from Phase 1b/2 Study of Onvansertib Demonstrates Response to Treatment in Relapsed/Refractory AMLDecember 3rd, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
